EcoDrugPlus

B-Raf Proto-Oncogene, Serine/threonine Kinase

Ensembl ID : ENSIPUG00000017122
Gene Symbol: BRAF
3 Cross references
220 Possible Orthologues:

Bcl2 Apoptosis Regulator A

Ensembl ID : ENSIPUG00000004823
Gene Symbol: BCL2A
3 Cross references
168 Possible Orthologues:

Bcl2 Apoptosis Regulator B

Ensembl ID : ENSIPUG00000012216
Gene Symbol: BCL2B
3 Cross references
176 Possible Orthologues:

Bcl2 Like 1

Ensembl ID : ENSIPUG00000013635
Gene Symbol: BCL2L1
3 Cross references
226 Possible Orthologues:

Bcl2 Like 10

Ensembl ID : ENSIPUG00000016501
Gene Symbol: BCL2L10
4 Cross references
127 Possible Orthologues:

Bcr Activator Of Rhogef And Gtpase

Ensembl ID : ENSIPUG00000012796
Gene Symbol: BCR
3 Cross references
205 Possible Orthologues:

Bruton Agammaglobulinemia Tyrosine Kinase

Ensembl ID : ENSIPUG00000017071
Gene Symbol: BTK
3 Cross references
204 Possible Orthologues:

C-C Motif Chemokine Receptor 9

Ensembl ID : ENSIPUG00000003778
Gene Symbol: CCR9
4 Cross references
193 Possible Orthologues:

C-X-C Motif Chemokine Receptor 1

Ensembl ID : ENSIPUG00000010701
Gene Symbol: CXCR1
4 Cross references
275 Possible Orthologues:

Dna (Cytosine-5-)-Methyltransferase 1

Ensembl ID : ENSIPUG00000004818
Gene Symbol: DNMT1
3 Cross references
210 Possible Orthologues:

Dna Topoisomerase I

Ensembl ID : ENSIPUG00000015990
Gene Symbol: TOP1
3 Cross references
198 Possible Orthologues:

Dna Topoisomerase Ii Alpha

Ensembl ID : ENSIPUG00000020828
Gene Symbol: TOP2A
3 Cross references
209 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).